ACRV Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $1.27 - $3.56

3.9 Year ACRV Performance Metrics:

Total Return (with DRIP): -87.4% (-41.24% CAGR)

Total Return (no DRIP): -86.0% (-39.64% CAGR)

Share Price: -87.7% (-41.55% CAGR)

Yield on Cost (with DRIP): 10.06%

Total Invested: $10,000

Total Value (with DRIP): $1,257

Total Return $ (with DRIP): -$8,743

Dividend Increase: 0.0% (0.00% CAGR)

Dividend Yield (FWD): 0.00% ($0.00)

ACRV 3.9-yr Total Return ($10K invested)

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ACRV Share Price

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

ACRV Price CAGR:1Y: 13.26%2Y: -45.88%5Y: -41.76%10Y: -41.76%

ACRV Dividend Payments & Yield

Dividend Payments & Yield

ACRV Dividend CAGR:1Y: -58.60%2Y: -58.60%5Y: -58.60%10Y: -58.60%

Annual Dividends (Total Paid Per Year)

Dividend Growth Year Over Year

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

ACRV Dividends Info:

Annual Dividend: $1.63992

Forward Yield: 80%

Ex-Dividend Date: 2022-12-21

Lifetime Dividends / Share: $2.46

ACRV Dividend History: Dates, Payments & Yield list

Below is a schedule of all ACRV dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
12/21/2022	12/23/2022	$0.137	13.76%	14.08%	$11.65
11/16/2022	11/18/2022	$0.137	9.79%	10.39%	$15.78
10/19/2022	10/21/2022	$0.137	0%	0%	$0.00
09/19/2022	09/21/2022	$0.137	0%	0%	$0.00
08/17/2022	08/19/2022	$0.137	0%	0%	$0.00
07/20/2022	07/22/2022	$0.137	0%	0%	$0.00
06/22/2022	06/24/2022	$0.137	0%	0%	$0.00
05/18/2022	05/20/2022	$0.137	0%	0%	$0.00
04/20/2022	04/22/2022	$0.137	0%	0%	$0.00
03/17/2022	03/21/2022	$0.410	0%	0%	$0.00
12/15/2021	12/17/2021	$0.410	0%	0%	$0.00
09/22/2021	09/24/2021	$0.410	0%	0%	$0.00

Projected Future Returns & Dividends for ACRV

Based on past 3.9-year performance, here are ACRV growth metrics:

Share price CAGR of -41.55%
Dividend CAGR of -58.6%

Using ACRV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ACRV (DRIP)	ACRV - No DRIP
Current Price	$2.05	$2.05
Start Shares	4,878.05	4,878.05
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	36,175.83	4,878.05
Dividends Payment	$0.00	$0.00
Annual Dividends	$1,743	$235
Yield on cost	17.43%	2.35%
Share Price	$0.24	$0.24
Total Dividends	$30,939	$13,250
Final Value	$8,659	$14,418

Estimated Future Value + Dividends - ACRV

NOTE: Above numbers are our estimate based on ACRV's Dividend and Price CAGR over past 3.9 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Acrivon Therapeutics, Inc. (ACRV) had its IPO on , and is traded on NASDAQ stock exchange.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.

ACRV website: https://acrivon.com